We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name Enasidenib
Trade Name Idhifa
Synonyms AG-221
Drug Descriptions

Idhifa (enasidenib) inhibits IDH2 to prevent 2HG formation, which may promote differentiation and inhibit proliferation of cancer cells (PMID: 28280273). Idhifa (enasidenib) is FDA-approved for use in patients with relapsed or refractory acute myeloid leukemia harboring an IDH2 mutation (R140Q/L/G/W, R172K/M/G/S/W) (FDA.gov).

DrugClasses IDH2 Inhibitor 5
CAS Registry Number 1446502-11-9
NCIT ID C111573

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Azacitidine + Enasidenib Azacitidine Enasidenib 3 4
Azacitidine + Enasidenib + Ivosidenib + Venetoclax Azacitidine Enasidenib Ivosidenib Venetoclax 0 0
Azacitidine + Enasidenib + Venetoclax Azacitidine Enasidenib Venetoclax 0 1
Cobimetinib + Enasidenib Cobimetinib Enasidenib 0 1
CPX-351 + Enasidenib CPX-351 Enasidenib 0 2
Cytarabine + Daunorubicin + Enasidenib Cytarabine Daunorubicin Enasidenib 0 1
Cytarabine + Enasidenib Cytarabine Enasidenib 0 2
Cytarabine + Enasidenib + Idarubicin Cytarabine Enasidenib Idarubicin 0 1
Decitabine and Cedazuridine + Enasidenib Decitabine and Cedazuridine Enasidenib 0 3
Decitabine and Cedazuridine + Enasidenib + Venetoclax Decitabine and Cedazuridine Enasidenib Venetoclax 0 3
Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Dexamethasone Enasidenib Ixazomib Pomalidomide 0 1
Enasidenib Enasidenib 37 15
Enasidenib + Etoposide + Mitoxantrone Enasidenib Etoposide Mitoxantrone 0 1
Enasidenib + Fedratinib Enasidenib Fedratinib 0 1
Enasidenib + Gilteritinib Enasidenib Gilteritinib 0 1
Enasidenib + Glasdegib Enasidenib Glasdegib 0 1
Enasidenib + Ivosidenib Enasidenib Ivosidenib 0 0
Enasidenib + Quizartinib Enasidenib Quizartinib 1 0
Enasidenib + Rituximab Enasidenib Rituximab 0 1
Enasidenib + Ruxolitinib Enasidenib Ruxolitinib 0 1
Enasidenib + Venetoclax Enasidenib Venetoclax 3 1


Additional content available in Icon for CKB-BoostCKB BOOST